NCT07044401View on ClinicalTrials.gov

A Single-dose Study to Investigate the Effect of Injection Site on KAI-9531 Relative Bioavailability in a Range of Body Mass Indices

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

51

Participants

Timeline

Start Date

July 14, 2025

Primary Completion Date

November 13, 2025

Study Completion Date

November 13, 2025

Conditions

Healthy Volunteers

Interventions

DRUG

KAI-9531

SC Injection.

Trial Locations (1)

85283

Celerion, Tempe

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Kailera

INDUSTRY